Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: A French nationwide study

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i104-i112

  Sacri, Anne Sylvia ^a   Chambaraud, Tristan ^b   Ranchin, Bruno ^c   Florkin, Benoît ^d   Sée, Hélène ^e   Decramer, Stéphane ^f   Flodrops, Hugues ^g   Ulinski, Tim ^h   Allain Launay, Emma ⁱ   Boyer, Olivia ^d   Dunand, Olivier ^j   Fischbach, Michel ^k   Hachulla, Eric ^l   Pietrement, Christine ^m   Le Pogamp, Patrick ⁿ   Stephan, Jean Louis ^o   Belot, Alexandre ^c   Nivet, Hubert ^p   Nobili, François ^q   Guillevin, Loic ^r   Quartier, Pierre ^d   Deschênes, Georges ^e   Salomon, Rémi ^d   Essig, Marie ^b   Harambat, Jérôme ^a   more..

^a HÔPITAL PELLEGRIN   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f HÔPITAL DES ENFANTS   (France)

^g Groupe Hospitalier Saint Pierre   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ Hopital Mere Enfant CHU de Nantes   (France)

^j Centre Hospitalier Departemental Felix Guyon   (France)

^k HÔPITAL DE HAUTEPIERRE   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m REIMS UNIVERSITY HOSPITAL   (France)

ⁿ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^o HÔPITAL NORD   (France)

^p CHU BRETONNEAU   (France)

^q UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^r NONE   (France)

more..

Author keywords

ANCA associated vasculitis; children; ESRD; outcome; relapse

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CHILD; CHILDHOOD; CLINICAL FEATURE; DEATH; DELAYED DIAGNOSIS; DISEASE CLASSIFICATION; END STAGE RENAL DISEASE; ETHNIC GROUP; FEMALE; FOLLOW UP; FRENCHMAN; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; MULTICENTER STUDY (TOPIC); ONSET AGE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPLICATION; FRANCE; IMMUNOLOGY; INCIDENCE; KIDNEY DISEASES; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE;

ADOLESCENT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHILD; ETHNIC GROUPS; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MICROSCOPIC POLYANGIITIS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84926666260     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv011     Document Type: Article

References (58)

1. Kallenberg CG. Pathophysiology of ANCA-associated small vessel vascu-litis. Curr Rheumatol Rep 2010; 12: 399-405
2. Wegener F. About a peculiar rhinogenic granulomatosis with marked involvement of the arterial system and kidneys. Beitr Pathol Anat 1939; 102: 30-68
3. Godman GC, Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Pathol 1954; 58: 533-553
4. van der Woude FJ. Anticytoplasmic antibodies in Wegener's granuloma-tosis. Lancet 1985; 2: 48
5. Walters MD, Savage CO, Dillon MJ et al. Antineutrophil cytoplasm antibody in crescentic glomerulonephritis. Arch Dis Child 1988; 63: 814-817
6. Hattori M, Kurayama H, Koitabashi Y et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol 2001; 12: 1493-1500
7. Grisaru S, Yuen GW, Miettunen PM et al. Incidence of Wegener's granu-lomatosis in children. J Rheumatol 2010; 37: 440-442
8. Chen M, Yu F, Zhang Y et al. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 2005; 81: 723-727
9. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-430
10. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoanti-bodies specific for myeloperoxidase cause glomerulonephritis and vascu-litis in mice. J Clin Invest 2002; 110: 955-963
11. Wilde B, van Paassen P, Witzke O et al. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011; 79: 599-612
12. Abdulahad WH, Stegeman CA, Kallenberg CG. Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2009; 14: 26-32
13. Berden AE, Kallenberg CG, Savage CO et al. Cellular immunity in Wege-ner's granulomatosis: characterizing T lymphocytes. Arthritis Rheum 2009; 60: 1578-1587
14. Nogueira E, Hamour S, Sawant D et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-asso-ciated vasculitis. Nephrol Dial Transplant 2010; 25: 2209-2217
15. Gan PY, Steinmetz OM, Tan DS et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 2010; 21: 925-931
16. McKinney EF, Lyons PA, Carr EJ et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16: 586-591, 1p following 591
17. Kallenberg CG. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go? Clin Exp Immunol 2011; 164(Suppl 1): 1-3
18. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
19. Langford CA. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011; 164(Suppl 1): 31-34
20. Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010; 11: 12
21. Dillon MJ. Vasculitis treatment-new therapeutic approaches. Eur J Pediatr 2006; 165: 351-357
22. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010; 363: 285-286
23. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclo-phosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469
24. Hiemstra TF, Walsh M, Mahr A et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-2388
25. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
26. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vas-culitis. Rheum Dis Clin North Am 2010; 36: 447-461
27. Rottem M, Fauci AS, Hallahan CW et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122: 26-31
28. Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17: 754-761
29. Akikusa JD, Schneider R, Harvey EA et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57: 837-844
30. Siomou E, Tramma D, Bowen C et al. ANCA-associated glomeruloneph-ritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol 2012; 27: 1911-1920
31. Cabral DA, Uribe AG, Benseler S et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60: 3413-3424
32. Ozen S, Pistorio A, Iusan SM et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010; 69: 798-806
33. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculit-ides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-227
34. Schwartz GJ, Munoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637
35. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
36. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636
37. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-617
38. Stone JH, Hoffman GS, Merkel PA et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vascu-litides (INSSYS). Arthritis Rheum 2001; 44: 912-920
39. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-1832
40. Stegmayr BG, Gothefors L, Malmer B et al. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 2000; 14: 208-213
41. Ellis EN, Wood EG, Berry P. Spectrum of disease associated with anti-neu-trophil cytoplasmic autoantibodies in pediatric patients. J Pediatr 1995; 126: 40-43
42. Valentini RP, Smoyer WE, Sedman AB et al. Outcome of antineutrophil cytoplasmic autoantibodies-positive glomerulonephritis and vasculitis in children: a single-center experience. J Pediatr 1998; 132: 325-328
43. Salomon R, Niaudet P, eds. Vascularites à ANCA chez l'enfant. Journées parisiennes de pédiatrie. Paris: Flammarion Médecine-Sciences, 2002
44. Yu F, Huang JP, Zou WZ et al. The clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese children. Pediatr Nephrol 2006; 21: 497-502
45. Orlowski JP, Clough JD, Dyment PG. Wegener's granulomatosis in the pediatric age group. Pediatrics 1978; 61: 83-90
46. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol 2006; 21: 46-53
47. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299-2309
48. Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 2004; 163: 425-434
49. Levine D, Akikusa J, Manson D et al. Chest CT findings in pediatric We-gener's granulomatosis. Pediatr Radiol 2007; 37: 57-62
50. Connolly B, Manson D, Eberhard A et al. CT appearance of pulmonary vasculitis in children. AJR Am J Roentgenol 1996; 167: 901-904
51. Wadsworth DT, Siegel MJ, Day DL. Wegener's granulomatosis in children: chest radiographic manifestations. AJR Am J Roentgenol 1994; 163: 901-904
52. Haliloglu M, Karcaaltincaba M, Toru M et al. CT presentation of Wege-ner's granulomatosis in a child: rapidly progressive changes of pulmonary nodules to cavities. Eur J Radiol 2000; 35: 12-14
53. Vanoni F, Bettinelli A, Keller F et al. Vasculitides associated with IgG anti-neutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol 2010; 25: 205-212
54. Arulkumaran N, Jawad S, Smith SW et al. Long-term outcome of paediat-ric patients with ANCA vasculitis. Pediatr Rheumatol Online J 2011; 9: 12
55. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
56. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophospha-mide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
57. Dolezalova P, Price-Kuehne FE, Özen S et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediat-ric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72: 1628-1633
58. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineu-trophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548